Get the Stockscreener App
3.29
4.11%
0.13
Voyager Therapeutics Inc stock is traded at $3.29, with a volume of 306.20K.
It is up +4.11% in the last 24 hours and up +11.90% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$3.16
Open:
$3.2
24h Volume:
306.20K
Relative Volume:
0.53
Market Cap:
$182.06M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
5.0615
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
+0.61%
1M Performance:
+11.90%
6M Performance:
-40.51%
1Y Performance:
-62.87%
1-Day Range:
$3.16
$3.37
1-Week Range:
$3.15
$3.37
52-Week Range:
$2.645
$9.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.29 | 170.16M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.45 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.01 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.75 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.56 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Is Voyager Therapeutics Inc. a good long term investmentHigh-yield trading alerts - Autocar Professional
Voyager Therapeutics Inc. Stock Analysis and ForecastExplosive market performance - jammulinksnews.com
What drives Voyager Therapeutics Inc. stock priceTriple-digit returns - jammulinksnews.com
Why Voyager Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Stock Analysis - Newser
Voyager Therapeutics’ Promising Alzheimer’s Study: A Potential Game-Changer? - MSN
Why did Voyager's net profit surge in Q4 2024 despite high operating expenses? - AInvest
What analysts say about Voyager Therapeutics Inc. stockMarket-crushing stock picks - Autocar Professional
Does Voyager Therapeutics Inc. stock pay reliable dividendsTrend Based Entry Alerts - beatles.ru
Voyager Therapeutics adds new gene therapy to Alzheimer’s program - BioWorld MedTech
Baird reiterates Outperform rating on Voyager Therapeutics stock with $18 price target - Investing.com Canada
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease - GlobeNewswire
How Voyager Therapeutics Inc. stock performs during market volatilityDaily Top Gainers - Newser
Voyager Therapeutics Introduces New Program Targeting Genetic Risk Factor of Alzheimer's Disease - 富途牛牛
Voyager Therapeutics Launches New Gene Therapy Program Targeting APOE for Alzheimer's Disease Treatment - Quiver Quantitative
Voyager Therapeutics unveils APOE-targeting Alzheimer’s therapy program By Investing.com - Investing.com South Africa
Voyager Therapeutics unveils APOE-targeting Alzheimer’s therapy program - Investing.com
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.
What makes Voyager Therapeutics Inc. stock price move sharplyBreakout Setup Scanner - Newser
Allspring Global Investments Holdings LLC Buys 21,149 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Brokerages - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Rhumbline Advisers - Defense World
Financial Comparison: Prime Medicine (NYSE:PRME) & Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics at H.C. Wainwright: Genetic Innovation in Focus By Investing.com - Investing.com Canada
Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspecti - GuruFocus
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | VYGR Stock News - GuruFocus
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
Millennium Management LLC Sells 60,935 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Squarepoint Ops LLC Decreases Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade) - Seeking Alpha
Voyager Therapeutics Approves Stock Plans at Annual Meeting - TipRanks
BNP Paribas Financial Markets Sells 43,210 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Holdings Lowered by ProShare Advisors LLC - Defense World
Deutsche Bank AG Cuts Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Voyager Therapeutics Inc Stock (VYGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Apr 02 '25 |
Sale |
3.43 |
10,885 |
37,336 |
430,931 |
4.89%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):